In recent years, immunotherapy has significantly improved the treatment of this disease and in particular the immune-checkpoint inhibitors against programmed cell death protein 1 (PD-1)/programmed death ligand 1(PD-L1) have improved the survival of non-small cell lung cancer (NSCLC) patients2–5. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.